查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1862631

子宫内膜癌治疗市场依治疗方法、药物类别、治疗线、给药途径及给药环境划分－2025-2032年全球预测

Endometrial Cancer Treatment Market by Treatment Type, Drug Class, Line Of Therapy, Mode Of Administration, Administration Setting - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，子宫内膜癌治疗市场将成长至 137.7 亿美元，复合年增长率为 5.64%。

关键市场统计数据
基准年 2024 88.7亿美元
预计年份：2025年 93.8亿美元
预测年份 2032 137.7亿美元
复合年增长率 (%) 5.64%

简要概述近期临床、诊断和护理服务的进展如何重塑当今子宫内膜癌的治疗模式。

子宫内膜癌的治疗正经历快速的临床和营运变革时期，这主要得益于分子生物学的突破、治疗方法创新以及医疗服务模式的转变。肿瘤谱分析和生物标记指导治疗选择的进步重塑了诊断路径，使临床医生能够摆脱对传统组织学检查的单一依赖，转而采用精准医疗方法来指导全身治疗方案的选择。同时，免疫调节剂和标靶药物的联合治疗为以往治疗选择有限的患者拓展了治疗选择，而微创手术技术和前哨淋巴结活检则降低了手术全期併发症，并缩短了患者的康復时间。

本文对模式转移创新、生物标记主导策略以及医疗保健去中心化等正在重塑子宫内膜癌治疗轨蹟的因素进行了分析概述。

子宫内膜癌的治疗格局正在经历变革，这主要得益于精准肿瘤学、免疫疗法联合治疗、不断改进的手术标准以及医疗服务分散化。分子分层提升了生物标记（例如错配修復状态和特定标靶突变）的重要性，这影响了临床试验的设计，并扩大了标靶治疗的适用患者群体。同时，PD-1抑制剂和CTLA-4标靶治疗策略的兴起，以及它们通常与抗血管生成药物和标靶治疗药物联合使用，标誌着治疗策略正朝着多药联合全身治疗的方向发展，以期在更多患者中实现持久疗效。

对2025年关税主导的贸易措施如何影响供应链韧性、筹资策略以及治疗和诊断管道的临床连续性进行观点评估

2025年美国关税政策为子宫内膜癌治疗生态系统带来了复杂的阻力和适应性挑战，影响了供应链、临床运作和筹资策略。部分进口药品成分、诊断剂和医疗设备关税的提高，增加了部分医疗机构和供应商的直接采购成本。为因应这项挑战，采购部门正在加快供应商多元化，探索替代采购方案，并加强与国内生产合作伙伴的协作，以降低关税波动带来的风险。同时，这些营运调整也在进行中，旨在维持临床试验的连续性，避免临床实验药物供应中断。

透过深度细分，将治疗类型、药物类别、治疗线、给药方式和医疗环境连结起来，从而指导研发和商业化选择。

在子宫内膜癌治疗领域，清晰的细分对于将临床创新转化为营运和商业优先事项至关重要。治疗类型细分包括化疗、联合治疗、荷尔蒙疗法、免疫治疗、放射治疗、放射线治疗和标靶治疗，每种治疗方式在研发、剂量和报销方面都有其独特的考量。依药物类别细分可以进一步拓展这一观点，区分抗血管生成药物、化疗药物、荷尔蒙疗法、化疗和分子标靶药物，并进一步细化细分，例如化疗中的含铂类药物和紫杉烷类药物、荷尔蒙疗法中的Aromatase抑製剂和孕激素、免疫治疗中的CTLA-4和PD-1抑製剂，以及分子标靶药物中的mTORTOR抑製剂、PARP抑製剂和蛋白酪氨酸激酶抑製剂。治疗线细分则将临床治疗顺序（第一线、二线、三线、四线及后续治疗）置于具体的脉络中，并指导临床试验终点、对照组的选择以及医保报销方案的製定。

区域性洞察解释了法规结构、诊断基础设施和报销模式如何影响全球市场中获得治疗的机会。

区域趋势对子宫内膜癌治疗和诊断的可近性途径、监管重点和普及率有显着影响。在美洲，监管机构和支付方优先考虑卫生技术评估 (HTA) 和真实世界证据，同时许多医疗系统正在投资分子诊断能力和门诊输液中心，以改善可及性并减少住院治疗。这些区域性优先事项促进了在诊断网络完善的地区快速采用生物标记驱动疗法，但也凸显了某些地区先进诊断可及性仍然不均衡的现状。

从公司层级进行的策略观察强调了投资组合多元化、伙伴关係模式和诊断整合是该领域的关键竞争优势。

製药、生物技术、诊断和医疗设备公司的企业策略正趋向于整合解决方案，将新型疗法与伴随诊断和患者支持项目相结合。主要企业致力于建立多元化的产品组合，力求在变革性免疫疗法和标靶治疗与成熟的治疗方法（如荷尔蒙疗法疗法和细胞毒性疗法）之间取得平衡；而小规模的专业公司则专注于独特的作用机制和生物标记主导的适应症。伙伴关係和策略联盟日益围绕着联合治疗的共同开发、旨在加速监管证据提交的联合设计试验以及旨在扩大地域覆盖范围的许可协议。

为指导诊断技术改进、供应链多元化、临床策略优化以及与支付方合作，确保医疗服务的可近性和影响力，提供切实可行的建议。

产业领导者应优先采取一系列协同行动，将临床创新转化为持久的患者获益，同时管控营运和市场进入风险。首先，需要投资建立强大的分子诊断计画和伙伴关係，以确保生物标记驱动疗法能够精准筛选出合适的患者。这包括提升病理诊断能力，并完善报销机制，避免诊断瓶颈。其次，应制定临床开发计划，评估从第一线治疗到后续治疗的各种方案和联合治疗，并纳入患者报告结局和真实世界证据，以加强与支付方的沟通，并优化指南制定。

对证据收集和三角验证过程进行透明描述，整合临床文献、註册登记资料、相关人员访谈和营运分析，以得出严谨的研究结果。

本分析所依据的研究结合了对监管指南、同行评审的临床文献、公共临床试验註册库的系统性回顾，以及对临床医生、支付方、诊断负责人和商业高管的专家访谈。二手资料提供了有关治疗机制、近期核准和指南变更以及外科和门诊护理进展的背景资讯。一手研究透过与在研究设计、检查室运营、医院采购和支付方决策方面经验丰富的相关人员进行定性对话，验证了战略检验，从而实现了对临床趋势和运营实际情况的三角验证。

整合临床创新和营运要务的最终结论，为改善整个护理路径中的患者预后提供连贯的视角。

总之，子宫内膜癌治疗领域呈现出一种良性张力，一方面是快速的临床创新，另一方面是将这些创新成果惠及患者所需的复杂运作。生物标记指导的选择、免疫疗法和标靶药物联合治疗，以及手术和门诊管理的改进，正在共同拓展治疗选择，同时也需要新的诊断、物流和支付方参与策略。同时，贸易政策的变化和区域基础设施的差异等外部因素，要求製造商、医疗服务提供者和支付方做出务实的调整，以确保患者能够获得治疗并持续参与临床试验。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • PD-1 和新型查核点标靶疗法合併治疗进行性子宫内膜癌
  • 透过整合分子谱和基因生物标誌物来建构个人化治疗策略
  • 早期子宫内膜癌患者中微创机器人辅助子宫切除术的使用日益增多
  • 开发抑制PI3K/AKT/mTOR路径的口服标靶治疗用于治疗復发性子宫内膜癌
  • 引入前哨淋巴结定位以减少子宫内膜癌分期手术併发症
  • 利用真实世界证据资料库优化子宫内膜癌的治疗流程和患者预后
  • 高风险子宫内膜癌试验中新兴的VEGF抑制剂和化疗联合策略
  • 扩大数位健康平台规模，用于远端监测子宫内膜癌患者的生活品质和不利事件
  • 促进与放射治疗技术进步的整合，例如用于治疗局部子宫内膜癌的近距离放射
  • 致力于研究如何弥合服务不足的子宫内膜癌患者群体在获得新型疗法方面的差距

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 子宫内膜癌治疗市场（依治疗方法）

  • 化疗
  • 联合治疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 放射线治疗
  • 外科手术
  • 标靶治疗

9. 依药物类别分類的子宫内膜癌治疗市场

  • 抗血管新生疗法
  • 化疗药物
    • 含铂类药物
    • 紫杉烷类
  • 荷尔蒙疗法
    • Aromatase抑制剂
    • 黄体素
  • 免疫疗法
    • CTLA-4抑制剂
    • PD-1抑制剂
  • 标靶治疗
    • mTOR抑制剂
    • PARP抑制剂
    • 蛋白酪氨酸激酶抑制剂

第十章 子宫内膜癌治疗市场（依治疗线划分）

  • 主要治疗
  • 四线治疗及以后
  • 二级治疗
  • 三级治疗

第十一章 依给药途径分類的子宫内膜癌治疗市场

  • 静脉注射
  • 口服

第十二章 子宫内膜癌治疗市场（依给药途径划分）

  • 门诊治疗
  • 住院设施
  • 医院门诊部

第十三章 各地区子宫内膜癌治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 子宫内膜癌治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国子宫内膜癌治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Eisai Co., Ltd.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca PLC
    • Pfizer Inc.
    • Novartis AG
    • Johnson & Johnson
    • Eli Lilly and Company
Product Code: MRR-521BAA36EC26

The Endometrial Cancer Treatment Market is projected to grow by USD 13.77 billion at a CAGR of 5.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.87 billion
Estimated Year [2025] USD 9.38 billion
Forecast Year [2032] USD 13.77 billion
CAGR (%) 5.64%

A concise introduction that contextualizes recent clinical, diagnostic, and care delivery advancements reshaping endometrial cancer treatment paradigms today

Endometrial cancer care has experienced an accelerated period of clinical and operational change driven by molecular insights, therapeutic innovation, and shifts in care delivery. Advances in tumor profiling and biomarker-driven treatment selection have reframed diagnostic pathways, enabling clinicians to move beyond histology alone toward precision approaches that guide systemic therapy choices. At the same time, combination regimens that pair immune modulation with targeted agents have expanded therapeutic options for patients who previously had limited choices, while minimally invasive surgical techniques and sentinel node mapping have reduced perioperative morbidity and shortened recovery timelines.

Transitioning from discovery to adoption, stakeholders across clinical, regulatory, and payer communities are aligning around evidence frameworks that emphasize meaningful clinical benefit and real-world effectiveness. Consequently, health systems and providers are adapting workflows to integrate outpatient-friendly administration modes and patient-reported outcome monitoring. These changes demand coordinated shifts in clinical operations, diagnostics infrastructure, and commercial strategies to ensure that innovations translate into improved patient outcomes and sustainable care pathways.

An analytical overview of paradigm-shifting innovations, biomarker-driven strategies, and care decentralization that are redefining endometrial cancer treatment pathways

The landscape of endometrial cancer treatment is undergoing transformative shifts driven by precision oncology, immunotherapy combinations, evolving surgical standards, and the decentralization of care. Molecular stratification has elevated the role of biomarkers such as mismatch repair status and specific actionable mutations, which in turn has influenced clinical trial design and broadened the population eligible for targeted interventions. Concurrently, the rise of PD-1 inhibitors and CTLA-4-directed strategies, often combined with antiangiogenic or targeted agents, illustrates a shift toward multimodal systemic regimens that seek to convert durable responses in a greater proportion of patients.

In parallel, care delivery is moving toward more outpatient-friendly models supported by oral targeted therapies and improved supportive care that reduce hospital stays. Surgical practice continues to evolve with less invasive approaches and enhanced recovery protocols that preserve quality of life. These dynamics are reinforcing cross-disciplinary collaborations among medical oncology, gynecologic surgery, radiation oncology, and molecular pathology. As a result, stakeholders are increasingly focused on evidence generation around combinatorial approaches, sequencing strategies across first line and subsequent lines of therapy, and the value proposition of precision diagnostics to guide therapeutic selection.

A clear-eyed assessment of how tariff-driven trade measures in 2025 have reshaped supply chain resilience, procurement strategies, and clinical continuity across treatment and diagnostic channels

The implementation of United States tariffs in 2025 has introduced a complex set of headwinds and adaptive responses across the endometrial cancer treatment ecosystem, touching supply chains, clinical operations, and procurement strategies. Increased duties on specific imported pharmaceutical components, diagnostic reagents, and medical devices have elevated direct procurement costs for some institutions and suppliers. In turn, procurement teams have accelerated supplier diversification, sought alternative sourcing agreements, and engaged more deeply with domestic manufacturing partners to mitigate exposure to tariff volatility. These operational adjustments have unfolded alongside efforts to preserve continuity of clinical trials and avoid interruptions to investigational agent supply.

Moreover, the tariffs have intensified scrutiny over inventory management and contractual terms across distributor networks, prompting stakeholders to renegotiate long-term agreements and to consider hedging strategies for critical consumables. Regulatory interactions and customs clearance processes have required closer coordination between manufacturers and supply chain partners to reduce lead times. Importantly, clinicians and health system leaders have focused on maintaining patient access by prioritizing treatment pathways that leverage locally produced agents or oral formulations less vulnerable to cross-border logistics constraints. Collectively, these adaptations reflect the sector's pragmatic approach to preserving treatment continuity and clinical research momentum in the face of evolving trade policy.

Deep segmentation-focused insights that connect treatment types, drug classes, lines of therapy, administration modes, and care settings to inform development and commercialization choices

Segmentation clarity is critical to translating clinical innovation into operational and commercial priorities across endometrial cancer care. Treatment type segmentation encompasses chemotherapy, combination therapy, hormone therapy, immunotherapy, radiation therapy, surgery, and targeted therapy, each of which presents different development, administration, and reimbursement considerations. Drug class granularity extends this view by distinguishing antiangiogenic therapy, chemotherapeutic agents, hormonal therapy, immunotherapy, and targeted therapy, with further subcategorization that highlights platinum based agents and taxanes under chemotherapeutics, aromatase inhibitors and progestins under hormonal therapy, CTLA-4 inhibitors and PD-1 inhibitors under immunotherapy, and mTOR inhibitors, PARP inhibitors, and tyrosine kinase inhibitors under targeted therapy. Line of therapy segmentation captures the clinical sequencing context across first line, second line, third line, and fourth line and beyond, which dictates trial endpoints, comparator selection, and payer narratives.

Mode of administration, separated into intravenous and oral delivery, informs site-of-care planning, adherence strategies, and patient support services. Meanwhile, administration setting-ambulatory care, hospital inpatient, and hospital outpatient-shapes operational workflows, capital requirements, and the economics of care delivery. Integrating these segmentation lenses enables stakeholders to pinpoint evidence gaps, prioritize development portfolios for specific clinical contexts, and design commercial models that reflect how treatments are used across real-world practice settings.

Regionally nuanced intelligence that explains how regulatory frameworks, diagnostic infrastructure, and reimbursement models influence therapeutic access across global markets

Regional dynamics exert a strong influence on access pathways, regulatory priorities, and adoption rates for endometrial cancer therapeutics and diagnostics. In the Americas, regulatory authorities and payers emphasize health technology assessment and real-world evidence, while many systems invest in molecular diagnostic capacity and outpatient infusion centers to improve access and reduce hospitalization. These regional priorities have supported rapid uptake of biomarker-driven treatments in settings with established diagnostic networks, but they have also underscored disparities where access to advanced diagnostics remains uneven.

Across Europe, Middle East & Africa, variations in national reimbursement frameworks, diagnostic infrastructure, and clinical guideline harmonization drive differentiated adoption. Stakeholders in these markets have placed emphasis on cross-border clinical collaborations, centralized pathology review for trial enrollment, and capacity building for precision diagnostics. In the Asia-Pacific region, accelerated investment in domestic biopharmaceutical capabilities, public-private partnerships, and expanding clinical trial activity have supported faster localization of novel agents. However, differences in regulatory pathways, pricing policies, and reimbursement timelines require tailored market entry strategies and adaptive evidence-generation plans to secure sustainable access across distinct national environments.

Strategic company-level observations that highlight portfolio diversification, partnership models, and diagnostic integration as key competitive differentiators in the sector

Corporate strategies across pharmaceutical, biotechnology, diagnostic, and device companies are converging on integrated solutions that pair novel therapeutics with companion diagnostics and patient support programs. Leading organizations focus on building diversified portfolios that balance transformational immunotherapies and targeted agents with established modalities such as hormonal and cytotoxic therapies, while smaller specialized firms concentrate on niche mechanisms and biomarker-driven indications. Partnerships and strategic alliances increasingly center on co-development of combination regimens, jointly designed trials that accelerate regulatory evidence, and licensing agreements that extend geographic reach.

In addition, contract research organizations and diagnostic manufacturers have intensified collaboration with sponsors to streamline trial enrollment through centralized testing and harmonized biomarker panels. Commercial teams are also evolving their engagement models to emphasize value communication toward payers and integrated delivery networks, leveraging health economic modeling and real-world data to substantiate comparative benefit. Across the competitive landscape, agility in clinical development, capabilities in companion diagnostics, and a demonstrated ability to negotiate access agreements will continue to separate market leaders from followers.

Action-oriented recommendations that guide leaders to strengthen diagnostics, diversify supply chains, optimize clinical strategies, and align payer engagement to secure access and impact

Industry leaders should prioritize a coordinated set of actions to translate clinical innovation into durable patient impact while managing operational and market access risks. First, invest in robust molecular diagnostic programs and partnerships to ensure accurate patient selection for biomarker-driven therapies; this includes supporting pathology capacity building and reimbursement pathways to avoid diagnostic bottlenecks. Next, design clinical development plans that evaluate sequencing and combinations across first-line and later lines of therapy, while embedding patient-reported outcomes and real-world evidence collection to strengthen payer discussions and guideline positioning.

Operationally, diversify supply chains and cultivate regional manufacturing partnerships to reduce tariff and logistical exposure, and adopt inventory strategies that preserve trial continuity. Commercially, develop value communication strategies that stress clinical differentiation, health economic impact, and adherence support, particularly for oral therapies that shift care to ambulatory and outpatient settings. Finally, engage early with payers and regulatory authorities to co-create evidence frameworks that accelerate access decisions and to pursue adaptive reimbursement approaches tied to outcomes data. Implementing these steps will enhance organizational resilience and increase the probability that clinical advances yield meaningful benefits at scale.

A transparent description of the evidence gathering and triangulation process integrating clinical literature, registries, stakeholder interviews, and operational analysis to produce rigorous insights

The research underpinning this analysis combined a structured review of regulatory guidance, peer-reviewed clinical literature, public clinical trial registries, and expert interviews with clinicians, payers, diagnostics leaders, and commercial executives. Secondary sources provided context on therapeutic mechanisms, recent approvals and guideline changes, and advances in surgical and outpatient care. Primary research validated strategic hypotheses through qualitative dialogues with stakeholders experienced in trial design, laboratory operations, hospital procurement, and payer decision-making, enabling triangulation of clinical trends with operational realities.

Data synthesis employed a thematic approach to map clinical innovations against care delivery models and regional access constraints. Methodological rigor included cross-validation of clinical endpoints, therapy sequences, and diagnostic dependencies, as well as sensitivity to policy and tariff shifts that affect supply chains. Limitations of the methodology include reliance on available public clinical data and stakeholder perspectives at a particular point in time; consequently, the analysis emphasizes evidence-based insights and actionable implications rather than speculative projections.

A definitive conclusion that synthesizes clinical innovations and operational imperatives into a coherent outlook for delivering improved patient outcomes across care pathways

In conclusion, the treatment landscape for endometrial cancer is characterized by a productive tension between rapid clinical innovation and the operational complexities required to deliver those advances to patients. Biomarker-driven selection, immunotherapy and targeted agent combinations, and improvements in surgical and outpatient management are converging to broaden therapeutic possibilities and to demand new diagnostic, logistical, and payer-aligned strategies. At the same time, external factors such as trade policy shifts and regional infrastructure variability require pragmatic adaptations by manufacturers, providers, and payers to safeguard access and clinical trial continuity.

Looking forward, success will accrue to organizations that integrate robust diagnostic capabilities, pursue rational combination and sequencing trials, and align commercial models with evolving care settings. By balancing scientific ambition with operational resilience and payer collaboration, stakeholders can convert promising clinical innovations into measurable improvements in patient outcomes and system sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of immunotherapy combinations targeting PD-1 and novel checkpoints in advanced endometrial cancer
  • 5.2. Integration of molecular profiling and genomic biomarkers for personalized endometrial cancer treatment strategies
  • 5.3. Increased adoption of minimally invasive robotic-assisted hysterectomy for early-stage endometrial cancer patients
  • 5.4. Development of oral targeted therapies inhibiting PI3K/AKT/mTOR pathway in recurrent endometrial carcinoma management
  • 5.5. Implementation of sentinel lymph node mapping to reduce surgical morbidity in endometrial cancer staging
  • 5.6. Utilization of real-world evidence databases to optimize treatment algorithms and patient outcomes in endometrial cancer
  • 5.7. Emergence of combination strategies pairing VEGF inhibitors with chemotherapy in high-risk endometrial cancer trials
  • 5.8. Growth of digital health platforms for remote monitoring of quality of life and adverse events in endometrial cancer patients
  • 5.9. Advances in radiotherapy techniques such as brachytherapy boost integration for localized endometrial carcinoma
  • 5.10. Focus on disparities research addressing access to novel therapeutics in underserved endometrial cancer populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endometrial Cancer Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Combination Therapy
  • 8.3. Hormone Therapy
  • 8.4. Immunotherapy
  • 8.5. Radiation Therapy
  • 8.6. Surgery
  • 8.7. Targeted Therapy

9. Endometrial Cancer Treatment Market, by Drug Class

  • 9.1. Antiangiogenic Therapy
  • 9.2. Chemotherapeutic Agents
    • 9.2.1. Platinum Based Agents
    • 9.2.2. Taxanes
  • 9.3. Hormonal Therapy
    • 9.3.1. Aromatase Inhibitors
    • 9.3.2. Progestins
  • 9.4. Immunotherapy
    • 9.4.1. CTLA-4 Inhibitors
    • 9.4.2. PD-1 Inhibitors
  • 9.5. Targeted Therapy
    • 9.5.1. MTOR Inhibitors
    • 9.5.2. PARP Inhibitors
    • 9.5.3. Tyrosine Kinase Inhibitors

10. Endometrial Cancer Treatment Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Fourth Line And Beyond
  • 10.3. Second Line
  • 10.4. Third Line

11. Endometrial Cancer Treatment Market, by Mode Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Endometrial Cancer Treatment Market, by Administration Setting

  • 12.1. Ambulatory Care
  • 12.2. Hospital Inpatient
  • 12.3. Hospital Outpatient

13. Endometrial Cancer Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Endometrial Cancer Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Endometrial Cancer Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Eisai Co., Ltd.
    • 16.3.4. Bristol-Myers Squibb Company
    • 16.3.5. F. Hoffmann-La Roche Ltd
    • 16.3.6. AstraZeneca PLC
    • 16.3.7. Pfizer Inc.
    • 16.3.8. Novartis AG
    • 16.3.9. Johnson & Johnson
    • 16.3.10. Eli Lilly and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENDOMETRIAL CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)

TABLE